Nexium capsules LDA Specific Clinical Experience Investigation

Study identifier:D961PC00002

ClinicalTrials.gov identifier:NCT01729182

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Nexium capsules Specific Clinical Experience Investigation for long-term use concerning prevention of recurrence of gastric ulcer or duodenal ulcer with LDA

Medical condition

Gastric Ulcer

Phase

Healthy volunteers

Study drug

Sex

All

Actual Enrollment

2363

Study type

Observational

Age

N/A

Date

Study Start Date: 01 Jan 2013

Primary Completion Date: 09 Mar 2017

Study Completion Date: 09 Mar 2017

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Aug 2019 by AstraZeneca

Collaborators

Inclusion and exclusion criteria

No locations available

Arms	Assigned Interventions
Nexium	-

Documents available

AZ_Synopsis_D961PC00002
Download
K. Sakamoto, M. Nii, T. Tokimoto and Y. Takumi Efficacy and Safety of Esomeprazole (Nexium) for the Prevention of Recurrent Gastric or Duodenal Ulcers in Patients on Continuous LDA; PMS of Long-term Use Jpn Pharmacol Ther, 47(6), 893 - 910, 2019
Download
Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Clinical Study Information

8002369933

[email protected]

Contact Backup

AstraZeneca Information (Outside US)

0018002369933

Investigators

Principal Investigator

Shigeru Yoshida

Astrazeneca K.K.